| UHC Medicaid Medical & Drug | Hearing Aids and Devices Including Wearable, Bone-Anchored, and Semi-Implantable – Community Plan Medical Policy | 2026-06-01 |
| UHC Medicaid Medical & Drug | Hemgenix® (Etranacogene Dezaparvovec-Drlb) – Community Plan Medical Benefit Drug Policy | 2026-06-01 |
| UHC Medicaid Medical & Drug | Hereditary Angioedema (HAE), Treatment and Prophylaxis – Community Plan Medical Benefit Drug Policy | 2026-06-01 |
| UHC Medicaid Medical & Drug | Ilumya® (Tildrakizumab-Asmn) – Community Plan Medical Benefit Drug Policy | 2026-06-01 |
| UHC Medicaid Medical & Drug | Intravenous Enzyme Replacement Therapy (ERT) for Gaucher Disease – Community Plan Medical Benefit Drug Policy | 2026-06-01 |
| UHC Medicaid Medical & Drug | Krystexxa® (Pegloticase) – Community Plan Medical Benefit Drug Policy | 2026-06-01 |
| UHC Medicaid Medical & Drug | Leqvio® (Inclisiran) – Community Plan Medical Benefit Drug Policy | 2026-06-01 |
| UHC Medicaid Medical & Drug | Lower Extremity Endovascular Procedures – Community Plan Medical Policy | 2026-06-01 |
| UHC Medicaid Medical & Drug | Manipulative Therapy – Community Plan Medical Policy | 2026-06-01 |
| UHC Medicaid Medical & Drug | Negative Pressure Wound Therapy – Community Plan Medical Policy | 2026-06-01 |